T1D Hypoglycemia Prediction Algorithms: A Systematic Review (Preprint)

2021 ◽  
Author(s):  
Stella Tsichlaki ◽  
Lefteris Koumakis ◽  
Manolis Tsiknakis

BACKGROUND Diabetes is a chronic condition that necessitates regular monitoring and self-management of the patient's blood glucose levels. People with type 1 diabetes (T1D) can live a productive life if they receive proper diabetes care. Nonetheless, a loose glycemic control might increase the risk of developing hypoglycemia. This incident can occur due to a variety of causes, such as taking additional doses of insulin, skipping meals, or over-exercising. Mainly, the symptoms of hypoglycemia range from mild dysphoria to more severe conditions, if not detected in a timely manner. OBJECTIVE In this review, we report on innovative detection techniques and tactics for identifying and preventing hypoglycemic episodes, focusing on type 1 diabetes. METHODS A systematic literature search following the PRISMA guidelines was performed focusing on the “PUBMED”, “Google Scholar”, “IEEE Xplore” and “ACM” digital libraries to find articles about technologies related to hypoglycemia detection in type 1 diabetes patients. RESULTS The presented approaches have been utilized or devised to enhance blood glucose monitoring and boost its efficacy to forecast future glucose levels, which could aid the prediction of future episodes of hypoglycemia. We detected nineteen predictive models for hypoglycemia, specifically on type 1 diabetes, utilizing a wide range of algorithmic methodologies, spanning from statistics (10%) to machine learning (52%) and deep learning (38%). The algorithms employed most are the kalman filtering and classification models (SVM, KNN, random forests). The performance of the predictive models was found overall to be satisfactory, reaching accuracies between 70% and 99% which proves that such technologies are capable to facilitate the prediction of T1D hypoglycemia. CONCLUSIONS It is evident that CGM can improve the glucose control in diabetes but predictive models for hypo- and hyper- glycemia using only mainstream noninvasive sensors such as wristbands and smartwatches are foreseen to be the next step for mHealth in T1D. Prospective studies are required to demonstrate the value of such models in real-life mHealth interventions.

2017 ◽  
Author(s):  
Ina Darashkevich ◽  
Tatiana Mochort ◽  
Lola Niconova ◽  
Serhey Tishkovsky

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 776-P
Author(s):  
RACHEL BRANDT ◽  
MINSUN PARK ◽  
LAURIE T. QUINN ◽  
MINSEUNG CHU ◽  
YOUNGKWAN SONG ◽  
...  

2021 ◽  
Vol 9 ◽  
Author(s):  
Jesus Dominguez-Riscart ◽  
Nuria Buero-Fernandez ◽  
Ana Garcia-Zarzuela ◽  
Fernando A. Marmolejo-Franco ◽  
Ana C. Perez-Guerrero ◽  
...  

The goal in type 1 diabetes (T1D) therapy is to maintain optimal glycemic control under any circumstance. Diabetes technology is in continuous development to achieve this goal. The most advanced Food and Drug Administration- and European Medicines Agency-approved devices are hybrid closed-loop (HCL) systems, which deliver insulin subcutaneously in response to glucose levels according to an automated algorithm. T1D is frequently encountered in the perioperative period. The latest international guidelines for the management of children with diabetes undergoing surgery include specific adjustments to the patient's insulin therapy, hourly blood glucose monitoring, and intravenous (IV) insulin infusion. However, these guidelines were published while the HCL systems were still marginal. We present a case of a 9-year-old boy with long-standing T1D, under HCL system therapy for the last 9 months, and needing surgery for an appendectomy. We agreed with the family, the surgical team, and the anesthesiologists to continue HCL insulin infusion, without further adjustments, hourly blood glucose checks or IV insulin, while monitoring closely. The HCL system was able to keep glycemia within range for the total duration of the overnight fast, the surgery, and the initial recovery, without any external intervention or correction bolus. This is, to the best of our knowledge, the first reported pediatric case to undergo major surgery using a HCL system, and the results were absolutely satisfactory for the patient, his family, and the medical team. We believe that technology is ripe enough to advocate for a “take your pump to surgery” message, minimizing the impact and our interventions. The medical team may discuss this possibility with the family and patients.


Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 136-OR
Author(s):  
MERYEM K. TALBO ◽  
VIRGINIE MESSIER ◽  
KATHERINE DESJARDINS ◽  
RÉMI RABASA-LHORET ◽  
ANNE-SOPHIE BRAZEAU ◽  
...  

2020 ◽  
pp. 13-49
Author(s):  
Eileen O'Donnell ◽  
Liam O'Donnell

The diagnosis of Type 1 Diabetes (T1D) will come as an unwelcome surprise to most people. Within a short period of time, the person will have to come to understand and manage this chronic illness. The terminology associated with the T1D condition will also be totally new to the person: diabetes mellitus, pancreas, hyperglycaemia (hyper), hypoglycaemia (hypo), bolus (fast acting insulin), basal (slow acting insulin), ketones and blood glucose levels. The purpose of this article is to assist newly diagnosed patients' understanding of T1D, people who are already living with T1D, carers of people with T1D, partners and family members of someone with T1D, work colleagues, and friends who participate in the same sporting activities or go on holiday with a person who has T1D. In addition, this article reviews how people living with T1D can still enjoy exercise and maintain the best quality of life possible; whilst controlling the blood glucose levels in their body for the rest of their lives to prevent the onset of complications associated with diabetes.


2019 ◽  
pp. 089719001985092 ◽  
Author(s):  
Kyle A. Farina ◽  
Michael P. Kane

Two Food and Drug Administration-approved programmed cell death-1 (PD-1) inhibitors, nivolumab (Opdivo®), and pembrolizumab (Keytruda®), are indicated for treatment-resistant malignancies. Inhibition of PD-1 also inhibits T-cell peripheral tolerance, enhancing autoimmunity. Various autoimmune conditions have been reported with the use of these agents, including type 1 diabetes mellitus (T1DM). This article reviews literature regarding the development of T1DM in patients treated with PD-1 inhibitors and identifies strategies for the appropriate identification, monitoring, and follow-up of these patients. Published cases of T1DM related to PD-1 inhibitor therapy were identified using PubMed. Eighty-three identified publications were reviewed, of which 37 publications involving 42 cases of anti-PD-1 therapy-induced T1DM were identified. The average age of patients at presentation was 62 years and 59.5% were male. The mean number of PD-1 inhibitor doses received was 5, with a mean time to presentation of 11 weeks. Initial presentation of diabetic ketoacidosis was reported in 69% of cases, with an average blood glucose of 660 mg/dL and an average HbA1cof 8.7%. The exact mechanism PD-1 inhibitor therapy-induced T1DM is unknown. Blood glucose monitoring is recommended for all patients receiving anti-PD-1 therapy. Further research is needed to delineate the frequency of this adverse effect, as well as to evaluate potential risk factors and ideal management strategies.


2015 ◽  
Vol 7 (S1) ◽  
Author(s):  
Gabriela Heiden Teló ◽  
Martina Schaan de Souza ◽  
Thaís Sturmer Andrade ◽  
Beatriz D'Agord Schaan

Sign in / Sign up

Export Citation Format

Share Document